Stay updated with breaking news from Clinical Development Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Detailed results from SURMOUNT-4, which showed Zepbound™ (tirzepatide) injection achieved superior mean percent change in body weight compared...
People who were randomized to placebo following the lead-in period experienced mean weight regain of 14.8% at 88 weeks, indicating Zepbound led to sustained weight loss compared to placebo Full results from the SURMOUNT-4 study were published in The Journal of the American Medical Association INDIANAPOLIS, Dec. 11, 2023 /PRNewswire/ — Detailed results from SURMOUNT-4, […]
Daiichi Sankyo and AstraZeneca’s ENHERTU showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population Results reaffirm...
First readout of two-year data from long-term extension study INDIANAPOLIS, Oct. 20, 2023 /PRNewswire/ -- Patients with moderate-to-severe atopic dermatitis who continued treatment with...
First readout of two-year data from long-term extension study ...